

Dr Pipasha Biswas discusses active surveillance with a focus on ADR'S at Pharmacovigilance gathering this spring

According to a recent study the global pharmacovigilance market is estimated to be worth US\$5,008.2 million by the end of 2019.

LONDON, LONDON, UNITED KINGDOM, March 25, 2015 / EINPresswire.com/ -- Stringent

"

Excellent speakers, professional, positive atmosphere, very good opportunity for networking, active discussions, adequate timelines, detailed discussions, thank you!" *Medac GmbH – previous attendee* government regulations, issues pertaining to public safety, toughened inspection regimes, coupled with the need of patients to report ailments immediately, has propelled growth in the global <u>pharmacovigilance</u> market.* Source: <u>http://bit.ly/18BYIUg</u>

SMi's 4th annual Pharmacovigilance, Drug Safety & Risk Management conference will share knowledge in risk assessment strategies and raise standards in drug safety when it returns to London this May. The show will aim to develop the competitive position of its attendees in a growing industry by providing the latest updates on good

pharmacovigilance practice through keynote sessions delivered by PharSafer Associates, Takeda, Quintiles, MedDRA, PRAC, Novartis and Pfizer.

<u>Click here</u> to see the full speaker line-up.

Highlights will include a Day 2 opening keynote address from industry experts, Symogen, who's clients include Roche, Pharma, Eisai, Glenmark and Astellas. Executive Director & QPPV, Dr Pipasha Biswas, will be discussing active surveillance with a focus on ADR'S, the drivers and restraints in pharmacovigilance, imperfect data and corporate responsibility.

Those who have already confirmed attendance include:

Bluefish pharmaceuticals, Daiichi Sankyo UK Ltd, Danish Medicines Agency, Drug Safety Research Unit, EudraVigilance Consultants, MedDRA Maintenance and Support Services Organisation (MSSO), NDA Regulatory Science, Novartis International AG, Novonordisk, Pfizer Ltd, pharsafer associates, ProductLife, Quintiles, Roche Products, Royal College of Physicians London, Solvay Pharmaceuticals, Takeda Chemical Industries, TEVA Pharmaceuticals, Vifor Pharma plus many more...

Further information and a brochure is available online at <u>www.pharmacovigilance-event.co.uk</u>

Pharmacovigilance, Drug Safety & Risk Management 11-12 May 2015 Holiday Inn Regents Park Hotel, London UK www.pharmacovigilance-event.co.uk



---END----

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <u>http://www.smi-online.co.uk</u>

Teri Arri SMi Group Ltd +44 (0)20 7827 6162 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/256665840

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.